Tafluprost

Tafluprost

DEA Class; Rx

Common Brand Names; Zioptan

  • Antiglaucoma, Prostaglandin Agonists

Prostaglandin analog
Used for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension
May increase pigmentation of eyelashes, iris, and/or eyelid skin

Indicated for the reduction of increased intraocular pressure in patients with open-angle glaucoma or ocular hypertension..

  • Conjunctival hyperemia (4-20%)
  • Ocular stinging (7%)
  • Ocular pruritus/allergic conjunctivitis (5%)
  • Cataract (3%)
  • Growth of eyelashes (2%)
  • Blurred vision (2%)

Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes

Caution with active intraocular inflammation (may exacerbate condition)

Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema

Pregnancy Category: C; teratogenic when administered IV in rats and rabbits

Lactation: Unknown whether distributed in breast milk

Adults

1 drop/day in each affected eye.

Geriatric

1 drop/day in each affected eye.

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Tafluprost 

ophthalmic solution

  • 0.0015% (0.015mg/mL)
DrugsAce
Logo